Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Builds Chronic Pain Business With NeuroTherm Acquisition

This article was originally published in The Gray Sheet

Executive Summary

NeuroTherm makes devices for radiofrequency ablation of nerves in painful facet joints in the neck or back to treat chronic pain. Although it markets neurostimulators, St. Jude currently does not sell any devices in the radio-frequency ablation segment of the pain-therapy market.

You may also be interested in...



St. Jude Warning Letter Spotlights CAPA Flaws At CardioMEMS Unit

The warning letter highlights validation and recordkeeping problems at the Atlanta manufacturing facility for the CardioMEMS heart failure remote monitoring system, but it is not expected to affect device availability.

St. Jude Medical Receives CE Mark For Prodigy Neurostimulation System

In March, St. Jude Medica received CE mark for its Prodigy Chronic Pain System with Burst Technology. According to the company, Prodigy is the only spinal cord stimulation device on the market that offers both tonic and burst stimulation to patients suffering from chronic pain.

Neuromodulation Market: Innovation Brings High-Growth Rewards

Neuromodulation is one of the largest and fastest growing segments of the worldwide medical device market, with global revenues expected to reach $6 billion by 2020;  as a result, the number of products in the neuromodulation pipeline is exploding. New and improved technologies will permit deeper penetration of neuromodulation therapies into existing patient groups as well as expansion of the market to new patient populations that could eventually number in the multi-millions.

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT033163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel